RxDoctor Payments DataLook up a doctor →

Shawn Macalester, DO

Rheumatology · Hillsboro, ORNPI 1871706218

Payments from drug & device makers

$219,598in general payments, 2019–2025

Across 1,073 payments — averaging $204.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$60K
  • Amgen$58K
  • AstraZeneca$23K
  • Bristol Myers Squibb$17K
  • Regeneron Healthcare Solutions, Inc.$12K
  • Sanofi$10K
  • plus $38K from 34 others

What the payments were for

  • Consulting fees$32,43415%
  • Speaking & faculty fees$138,37263%
  • Travel & lodging$24,05711%
  • Food & beverage$24,49211%
  • Education$2430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$219,598 in reported general payments places this provider in the 90th percentile of 79 rheumatology providers in Oregon.

See all rheumatology providers in Oregon

Medicare billing

Part B allowed, 2024
$2,544,515
Medicare patients
428
Services billed
132,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab38$936,280
TremfyaGuselkumab47$636,465
Enbrel SureclickEtanercept65$486,653
Orencia ClickjectAbatacept65$390,072
Cyltezo(Cf) PenAdalimumab-Adbm36$368,117
Cosentyx Unoready PenSecukinumab38$334,077
OtezlaApremilast75$333,170
Xeljanz XrTofacitinib Citrate43$266,278
RinvoqUpadacitinib30$262,191
Humira(Cf) PenAdalimumab30$247,332
Cosentyx Sensoready (2 Pens)Secukinumab29$215,635
OrenciaAbatacept34$207,509
XeljanzTofacitinib Citrate34$201,047
EnbrelEtanercept26$191,286
Cimzia (2 Pack)Certolizumab Pegol20$136,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Tremfya$60,284$1,572,74685 claims
AmgenOtezla, Enbrel$58,390$524,456101 claims
AbbVieRinvoq$8,671$262,19130 claims
E.r. Squibb & Sons, L.L.C.Orencia$462$207,50934 claims
PfizerXeljanz$7,641$201,04734 claims
UCB, Inc.Cimzia (2 Pack)$977$136,56320 claims
SanofiKevzara$10,435$109,79125 claims
GSKBenlysta$540$69,29513 claims
Antares Pharma, Inc.Otrexup$19$13,74120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 rheumatology providers in Oregon.

Other rheumatology in Hillsboro

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →